How Are Payers Controlling Costs With New Hepatitis C Treatments?

The recent growth of Hepatitis C treatment, now has payers considering the HCV category right up there with cancer, rheumatoid arthritis, and multiple sclerosis. Take a look at the recent approval of new hepatitis C treatments in Specialty Pharmacy Times’, Keeping an Eye on Hepatitis C Virus Drug Approvals, available here. (Source: :Lee Goldberg, Specialty Pharmacy Times, 8/20/14).

You might also be interested in:

Executives Talk Blockchain, EMR with Value & Outcomes October 19, 2018
Relentless Health Value’s Richter, #HCBiz Show!’s… August 2, 2018
Study: ICER Value Assessments Could Leave Medicare Part B… June 2, 2018
Time to Market: Accelerating Market Access January 4, 2019
Pharmacy Times, Specialty Pharmacy Times Earn Hermes Creative Awards June 1, 2018
Express Scripts Formulary Has Hep C, MS Exclusions August 20, 2018
Study: Evidence Supporting Breakthrough Drugs Often Limited July 23, 2018